Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
Interviews
25 August 2015
Continuing her company profiles, Sophia Ktori finds that Waters NuGenesis is differentiated because it can capture data from any instrument in the laboratory
07 July 2015
Continuing her series profiling companies providing informatics software, Sophia Ktori looks at the innovative technology of Core Informatics
07 July 2015
Sophia Ktori profiles IDBS, a company focusing on analytics as well as informatics
24 April 2015
Lonza Biosciences MODA system offers not just a paperless but a mobile and sanitisable way to carry out microbiology testing. Sophia Ktori reports
24 April 2015
Autoscribes LIMS has more than the usual applications, from lotteries to vehicle rentals, as Sophia Ktori discovers
10 February 2015
What happens when a relatively small informatics company is acquired by a very large healthcare corporation? Tom Wilkie looks at the case of Abbott Informatics and Starlims
Pages
Latest issue
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
